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Abstract: The vast majority of people living with human immunodeficiency virus (HIV)/acquired 
immune deficiency syndrome reside in the developing world, in settings characterized by lim-
ited health budgets, critical shortages of doctors, limited laboratory monitoring, a substantial 
burden of HIV in children, and high rates of coinfection, in particular tuberculosis. Therefore, 
the extent to which new antiretrovirals will contribute to improvements in the management of 
HIV globally will depend to a large extent on their affordability, ease of use, low toxicity profile, 
availability as pediatric formulations, and compatibility with tuberculosis and other common 
drugs. We undertook a systematic review of the available evidence regarding drug interactions, 
and the efficacy and safety of rilpivirine (also known as TMC-278), and assessed our findings 
in view of the needs and constraints of resource-limited settings. The main pharmacokinetic 
interactions relevant to HIV management reported to date include reduced bioavailability of 
rilpivirine when coadministered with rifampicin, rifabutin or acid suppressing agents, and reduced 
bioavailability of ketoconazole.   Potential recommendations for dose adjustment to compensate 
for these interactions have not been elaborated. Trials comparing rilpivirine and efavirenz found 
similar   outcomes up to 96 weeks in intent-to-treat analysis; failure of rilpivirine was mainly 
  virological, whereas failure among those exposed to efavirenz was mainly related to the occur-
rence of adverse events. Around half of the patients who fail rilpivirine develop non-nucleoside 
reverse transcriptase inhibitor resistance mutations. The incidence of Grade 2–4 events was 
lower for rilpivirine compared with efavirenz. Grade 3–4 adverse events potentially related to 
the drugs were infrequent and statistically similar for both drugs. No dose-response relationship 
was observed for efficacy or safety, and the lowest dose (25 mg) was selected for further clinical 
development. The potential low cost and dose of the active pharmaceutical ingredient means that 
rilpivirine can potentially be manufactured at a low price. Moreover, its long half-life suggests 
the potential for monthly dosing via nonoral routes, with promising early results from studies 
of a long-acting injectable formulation. These characteristics make rilpivirine an attractive drug 
for resource-limited   settings. Future research should assess the potential to improve robustness 
and assess the clinical significance of interaction with antituberculosis drugs.
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Introduction
Combination antiretroviral therapy has transformed the prognosis and life expectancy of 
people living with human immunodeficiency virus (HIV)/acquired immune deficiency 
syndrome (AIDS) in both resource-rich1 and resource-limited2 settings. For patients to 
be able to benefit from these gains in the long term, antiretroviral medicines must be 
convenient, safe, tolerable, effective, and affordable. The main drug-related   challenges 
to remaining on a particular regimen include side effects, interactions with other HIV/AIDS – Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
36
Ford et al
medications, safety during pregnancy, dosing schedules, 
pill burden, and degree of robustness against development 
of drug resistance.3
International treatment guidelines recommend using 
efavirenz, a non-nucleoside reverse transcriptase inhibi-
tor (NNRTI), as part of the standard first-line regimen. 
Efavirenz is potent, relatively well tolerated, and easy to 
monitor. However, its use is limited by its low genetic bar-
rier to development of resistance, its potential for central 
nervous system toxicity, concerns about safety in the first 
trimester of pregnancy,4 and its relatively high cost. Among 
the alternative NNRTIs in development, rilpivirine has 
received attention as a potentially important drug for use in 
resource-limited settings because of its low manufacturing 
cost, its ability to be coformulated with other antiretrovirals, 
and its favorable safety profile.
A number of expert reviews have been published sum-
marizing various characteristics of rilpivirine.5–8 In order to 
update and complement these expert reviews, we undertook 
a systematic review of the available evidence regarding 
the safety, efficacy, and pharmacokinetics of rilpivirine, 
and discuss here the potential implications of this drug for 
resource-limited settings.
Search strategy
We searched the following databases from inception to March 
2011 for articles containing rilpivirine or TMC-278:   Medline 
via PubMed, Embase, Lilics, Toxnet, and the Cochrane 
Central Register of Controlled Trials. We also searched 
the websites of major HIV conferences, ie, all international 
AIDS society conferences (up to Vienna, August 2010), all 
conferences on retroviruses and opportunistic infections 
(up to Boston, March 2011), and all abstracts from the 
international congresses on drug therapy in HIV infection 
(up to Glasgow, November 2010). No language restrictions 
were applied. We included all articles reporting original 
data on pharmacokinetics, tolerability, safety, and efficacy. 
This information was crosschecked against data presented in 
secondary reports (nonsystematic reviews, opinion articles, 
and news items). We also searched in the clinical trial.gov 
website to obtain information about ongoing studies. Finally, 
we complemented the search by reviewing bibliographies of 
relevant papers.
Our initial search yielded 292 articles and 31 conference 
abstracts. After screening out duplicates and items that did 
not meet our inclusion criteria, we retained six full-length 
articles and 16 conference abstracts. Articles comprised 
three clinical trials,9–11 one pharmacokinetic study,12 and 
two formulation studies.13,14 Conference abstracts yielded 
  additional data from two clinical trials,15,16 13   pharmacokinetic 
studies,17–29 and one bioequivalence study.30 All studies were 
published in English.
Pharmacology
The mode of action of rilpivirine is at the stage of viral 
genome replication, inhibiting HIV reverse transcriptase 
by binding to a hydrophobic pocket near the active site of 
the enzyme and thus preventing transcription of viral RNA. 
Rilpivirine is active against HIV-1 in a variety of NNRTI-
resistant clinical isolates, and the relatively high potency of 
rilpivirine compared with the older generation of NNRTIs 
is thought to be due to its internal conformational flexibility 
(“wiggling”) and the plasticity of its interaction with the 
binding site (“jiggling”).31
Pharmacokinetics
Rilpivirine is highly protein-bound, and more than 99% 
may be bound to human plasma proteins in a concentration-
dependent manner.31 Under fasting conditions, the maximum 
plasma concentration of rilpivirine (Cmax) decreased by 46% 
and the area under the rilpivirine plasma concentration curve 
(AUC) decreased by 43%. Similarly, rilpivirine Cmax and 
AUC are reduced by 50% when given with a protein-rich 
nutritional drink.32 As a consequence, it is recommended to 
take rilpivirine with food but avoid taking after a protein-rich 
drink. In a 7-day pharmacokinetic study of oral administra-
tion of rilpivirine 25 mg, 50 mg, 100 mg, and 150 mg once 
daily, Cmax was generally reached 3–4 hours after dosing.32 
Plasma concentrations were increased 2–3-fold from day 1 
to day 7. Drug elimination from the plasma was slow, with 
a terminal half-life of 34–55 hours.22 At higher doses, there 
was a trend towards greater interindividual pharmacokinetic 
variability, but plasma concentrations did not increase pro-
portionately with dose. A pediatric granule formulation has 
been developed, and its exposure under fasting conditions 
was comparable with the tablet formulation if taken with 
food (the AUC∞ was 26% higher when taken with food19). 
The main clearance of rilpivirine is via oxidative metabolism 
followed by sulfate conjugation or O-glucuronidation and 
N-glucuronidation in animal studies.32 Metabolic studies 
in human hepatocytes showed slow metabolic clearance, 
and #0.03% was found unchanged in the urine.22
Drug–drug interactions
The main results of drug–drug interaction studies are 
described below and summarized in Table 1.HIV/AIDS – Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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Interaction with key drugs  
in the management of HIV/AIDS
Tuberculosis drugs
Two pharmacokinetic studies have investigated the   interaction 
between rilpivirine and two drugs commonly used to treat 
tuberculosis, ie, rifampicin and rifabutin. Rifampicin dosed 
at 600 mg once daily together with rilpivirine 150 mg once 
daily was found to reduce rilpivirine AUC24h, Cmax, and Cmin 
by 80%, 69%, and 89%, respectively, when given to 16 
HIV-negative volunteers for 7 days.22 No significant change 
was seen in the pharmacokinetics of rifampicin. The study 
investigators concluded that concurrent administration of 
rilpivirine and rifampicin is not recommended.
In an 11-day study of rilpivirine 150 mg once daily and 
rifabutin 300 mg once daily in 18 HIV-negative volunteers, 
the AUC24h, Cmax, and Cmin of rilpivirine was reduced by 46%, 
35%, and 49%, respectively. The AUC24h of rifabutin and its 
metabolite, 25-O-desacetyl-rifabutin, were not affected by 
coadministration of rilpivirine.18
Both of these interactions are important for high-HIV 
burden settings where rates of tuberculosis/HIV coinfection 
are high.23 Clinical and dose-adjustment studies of rilpivirine 
coadministered with rifabutin or rifampicin are needed before 
coadministration is definitively ruled out.
Antiretrovirals
Several studies have assessed the pharmacokinetic interac-
tion between rilpivirine and other antiretrovirals. A study of 
rilpivirine and tenofovir, a nucleoside reverse transcriptase 
inhibitor (NRTI), in 15 healthy volunteers did not show any 
significant difference in the exposures of both drugs. The 
AUC24h of tenofovir was increased by 24%; while this increase 
was statistically significant, it was not considered to be clini-
cally relevant.33 Another study looking at rilpivirine 150 mg 
once daily dosed concomitantly with darunavir/ritonavir 
800/100 mg once daily in 16 HIV-negative volunteers found 
an important increase in rilpivirine exposure (AUC24h 130%, 
Cmax 79%, Cmin 178%).29 Three participants discontinued the 
study due to Grade 2 adverse events of diarrhea and abdomi-
nal pain (one volunteer on rilpivirine alone) and enteritis and 
maculopapular rash (volunteers on rilpivirine and darunavir/
ritonavir). The effect of increased rilpivirine exposure when 
coadministered with darunavir/ritonavir was confirmed by a 
second study which concluded that this was due to cytochrome 
P450 (CYP)3A4 inhibition.24 No clinically significant change 
in the pharmacokinetics of darunavir/ritonavir was seen. The 
clinical significance of this interaction and magnitude at lower 
doses of rilpivirine has not been assessed.
Antifungals
Ketoconazole, an azole antifungal, is a known inhibitor of 
CYP3A4, and coadministration (400 mg once daily) with 
rilpivirine 150 mg once daily in 16 HIV-negative volunteers 
resulted in an increase in AUC24h, Cmax, and Cmin by 49%, 
30%, and 76%, respectively, for rilpivirine.34 Conversely, 
the AUC24h, Cmax, and Cmin of ketoconazole decreased by 
24%, 15%, and 66%, respectively. It is unknown if the final 
marketed dose of rilpivirine 25 mg once daily warrants dose 
adjustment when these two drugs are coadministered.
Methadone
A modest change in the pharmacokinetics of   methadone 
was observed when coadministered with rilpivirine 
25 mg once daily in a pharmacokinetic study involving 
13   HIV-negative volunteers on dose-individualized metha-
done therapy. The Cmin, Cmax, and AUC24h of R-methadone 
and S-methadone were found to decrease by 24%, 14%, 16%, 
respectively, and by 21%, 13%, and 16%,   respectively.25 
  Rilpivirine   pharmacokinetics remained within normal range 
in the   presence of methadone. As a result of this study, 
clinical monitoring for methadone withdrawal symptoms is 
  recommended because methadone maintenance therapy may 
need to be adjusted in some patients.
Interactions with other drugs
Both rilpivirine and atorvastatin (a HMG-CoA reductase 
inhibitor) are substrates of CYP3A. A study in 16 
  HIV-negative volunteers administered rilpivirine 150 mg 
once daily and atorvastatin 40 mg once daily found no 
changes in rilpivirine exposures.26 However, atorvastatin 
exposures were increased with the sum of atorvastatin and its 
two active metabolites, ie, AUC24h increased by 21% while 
Cmax increased by 35%. All volunteers completed the study, 
with no Grade 3 or 4 adverse events reported, so no dose 
  adjustment was recommended.
Rilpivirine is shown to have decreased solubility at 
increased pH in vitro, and coadministration of famotidine 
40 mg once daily 2 hours before rilpivirine 150 mg once 
daily in a study of 24 HIV-negative subjects resulted in 
reduced exposures of rilpivirine AUC∞ and Cmax by 76% 
and 85%, respectively.35 The rilpivirine AUC∞ was increased 
by 13% when famotidine was administered 4 hours after 
  rilpivirine. No significant changes in the pharmacokinetics 
of either drug were noted when famotidine was administered 
12 hours before rilpivirine. The conclusion of this study was 
that administration of acid-suppressing agents should be 
adequately spaced apart.HIV/AIDS – Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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Table 1 Interactions between rilpivirine and other drugs
Coadministered drug Participants Duration Dose PK 
Rilpivirine
PK 
Coadministered drug
Comments
Rilpivirine Coadministered drug Cmax AUC24h Cmin Cmax AUC24h Cmin
Rifabutin18 18 HIV-negative volunteers 11 days 150 mg qd 300 mg qd 35% 46% 49% NC NC NC Reduced rilpivirine exposure due to 
CYP3A4 induction by rifabutin
Rifampicin22 16 HIV-negative volunteers 7 days 150 mg qd 600 mg qd 69% 80% 89% NC NC NC Reduced rilpivirine exposure due 
to CYP3A4 induction by rifampicin
Darunavir/ritonavir24 16 HIV-negative volunteers Session 1 – RIL 11 days 
Session 2 – DVR/r 22 days, 
RIL 11 days
150 mg qd 800 mg/100 mg qd ↑79% ↑130% ↑178% 10% 11% 11% Increased rilpivirine exposure 
due to CYP3A4 inhibition; the 
increase is not clinically relevant 
and no dose modification is 
recommended
Tenofovir33 15 healthy volunteers Session 1 – RIL 8 days 
Session 2 – TDF 16 days, 
RIL 8 days
150 mg qd 300 mg qd 3% ↑2% NC ↑21% ↑24% ↑24% Increase in TDF exposure is not 
clinically relevant and no dose 
modification is recommended
Atorvastatin26 16 HIV-negative volunteers Session 1 – Atorvastatin 4 days 
Session 2 – RIL 14 days, 
atorvastatin 4 days
150 mg qd 40 mg qd NC NC NC ↑35% ↑21% (total HMG-CoA 
reductase  activity)
NC No dosage adjustment needed
Ketoconazole34 16 healthy subjects 11 days 150 mg qd 400 mg qd ↑30% ↑49% ↑76% 15% 24% 66% Increased RIL exposure due to 
CYP3A4 inhibition by  
ketoconazole
Famotidine35 24 HIV-negative subjects Famotidine administered 
2 hours before, 12 hours before and  
4 hours after rilpivirine
150 mg qd 40 mg qd 85%  
(2 hours  
before)
AUC∞ 76% 
(2 hours  
before)
? NC NC NC Acid suppressing agent such as 
famotidine reduce bioavailability 
of RIL and therefore should be 
adequately space apart when given 
together
Sildenafil28 16 HIV-negative 
male volunteers
12 days RIL 75 mg qd and 50 mg sildenafil  
on day 12
75 mg qd 50 mg one dose NC NC NC NC NC NC No dosage adjustment needed
ethinylestradiol 
and norethindrone27
18 HIV-negative 
female volunteers
3 oral contraceptive cycles 25 mg qd ethinylestradiol 35 µg and 
norethindrone 1 mg
NC NC NC eST: ↑17%
Ne: NC
eST: NC
Ne: NC
eST: NC
Ne: NC
No dosage adjustment needed
Methadone25 13 HIV- negative volunteers 25 mg qd 60–100 mg dose  
individualized
NC NC NC R-methadone: 14%
S-methadone: 13%
R-methadone: 16% 
S-methadone: 16%
R-methadone: 24%
S-methadone: 21%
Clinical monitoring for methadone 
withdrawal symptoms is 
recommended
Abbreviations: AUC24h, area under the curve over 24 hours; AUC∞, area under the curve zero to infinity; Cmax, maximum concentration; Cmin, minimum concentration; 
DRV, darunavir; eST, ethinylestradiol; Ne, norethindrone; NC, no change; P, pharmacokinetics; qd, once daily; RIL, rilpivirine; TDF, tenofovir.
A pharmacokinetic study of 18 HIV-negative female 
volunteers on oral contraceptives (norethindrone 1 mg and 
ethinylestradiol 35 µg) and rilpivirine (25 mg once daily) 
was carried out for three cycles27 and found no significant 
pharmacokinetic changes in any of the drugs. There was 
an increase of 17% in the Cmax of ethinylestradiol in the 
presence of rilpivirine, but this was not considered to be 
clinically relevant. Serum levels of progesterone, luteinizing 
hormone, and follicle-stimulating hormone taken on days 1 
and 14 of the cycle were within normal ranges. Therefore, 
no dose adjustment is recommended during coadministra-
tion of rilpivirine and norethindrone/ethinylestradiol-based 
contraceptives.
Finally, a study assessing the pharmacokinetics of rilpi-
virine (75 mg once daily for 12 days) when coadministered 
with sildenafil (50 mg on day 12) and its active metabolites 
found no significant change when both were coadministered 
in a study of 16 HIV-negative male volunteers.28
Clinical efficacy
Data on the clinical efficacy of rilpivirine have been 
reported from three completed trials and two ongoing trials 
(Table 2).
Antiviral activity and safety was established in a Phase IIa 
trial that randomized 47 antiretroviral-naïve adult males to 
rilpivirine monotherapy or placebo. In this trial, rilpivirine 
achieved a statistically significant median viral load reduc-
tion, and 12.1% of participants (4/36) in the rilpivirine 
groups reached a viral load of ,400 copies/mL on day 8 
compared with no subjects in the placebo group.9 No changes 
in viral genotype or phenotype of the treated subjects were 
identified.HIV/AIDS – Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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Table 1 Interactions between rilpivirine and other drugs
Coadministered drug Participants Duration Dose PK 
Rilpivirine
PK 
Coadministered drug
Comments
Rilpivirine Coadministered drug Cmax AUC24h Cmin Cmax AUC24h Cmin
Rifabutin18 18 HIV-negative volunteers 11 days 150 mg qd 300 mg qd 35% 46% 49% NC NC NC Reduced rilpivirine exposure due to 
CYP3A4 induction by rifabutin
Rifampicin22 16 HIV-negative volunteers 7 days 150 mg qd 600 mg qd 69% 80% 89% NC NC NC Reduced rilpivirine exposure due 
to CYP3A4 induction by rifampicin
Darunavir/ritonavir24 16 HIV-negative volunteers Session 1 – RIL 11 days 
Session 2 – DVR/r 22 days, 
RIL 11 days
150 mg qd 800 mg/100 mg qd ↑79% ↑130% ↑178% 10% 11% 11% Increased rilpivirine exposure 
due to CYP3A4 inhibition; the 
increase is not clinically relevant 
and no dose modification is 
recommended
Tenofovir33 15 healthy volunteers Session 1 – RIL 8 days 
Session 2 – TDF 16 days, 
RIL 8 days
150 mg qd 300 mg qd 3% ↑2% NC ↑21% ↑24% ↑24% Increase in TDF exposure is not 
clinically relevant and no dose 
modification is recommended
Atorvastatin26 16 HIV-negative volunteers Session 1 – Atorvastatin 4 days 
Session 2 – RIL 14 days, 
atorvastatin 4 days
150 mg qd 40 mg qd NC NC NC ↑35% ↑21% (total HMG-CoA 
reductase  activity)
NC No dosage adjustment needed
Ketoconazole34 16 healthy subjects 11 days 150 mg qd 400 mg qd ↑30% ↑49% ↑76% 15% 24% 66% Increased RIL exposure due to 
CYP3A4 inhibition by  
ketoconazole
Famotidine35 24 HIV-negative subjects Famotidine administered 
2 hours before, 12 hours before and  
4 hours after rilpivirine
150 mg qd 40 mg qd 85%  
(2 hours  
before)
AUC∞ 76% 
(2 hours  
before)
? NC NC NC Acid suppressing agent such as 
famotidine reduce bioavailability 
of RIL and therefore should be 
adequately space apart when given 
together
Sildenafil28 16 HIV-negative 
male volunteers
12 days RIL 75 mg qd and 50 mg sildenafil  
on day 12
75 mg qd 50 mg one dose NC NC NC NC NC NC No dosage adjustment needed
ethinylestradiol 
and norethindrone27
18 HIV-negative 
female volunteers
3 oral contraceptive cycles 25 mg qd ethinylestradiol 35 µg and 
norethindrone 1 mg
NC NC NC eST: ↑17%
Ne: NC
eST: NC
Ne: NC
eST: NC
Ne: NC
No dosage adjustment needed
Methadone25 13 HIV- negative volunteers 25 mg qd 60–100 mg dose  
individualized
NC NC NC R-methadone: 14%
S-methadone: 13%
R-methadone: 16% 
S-methadone: 16%
R-methadone: 24%
S-methadone: 21%
Clinical monitoring for methadone 
withdrawal symptoms is 
recommended
Abbreviations: AUC24h, area under the curve over 24 hours; AUC∞, area under the curve zero to infinity; Cmax, maximum concentration; Cmin, minimum concentration; 
DRV, darunavir; eST, ethinylestradiol; Ne, norethindrone; NC, no change; P, pharmacokinetics; qd, once daily; RIL, rilpivirine; TDF, tenofovir.
This study was followed by a Phase II open-label trial 
evaluating the antiviral activity of rilpivirine adminis-
tered at three different doses (25 mg, 50 mg, or 150 mg) 
replacing either the protease inhibitor or an NNRTI of an 
ongoing failing treatment regimen.10 In this nonrandom-
ized, noncomparative trial, 36 patients were assessed for 
short-term (7-day) changes in viral load. Overall, the 
median change from baseline was −1.19 log10 copies/
mL in the protease inhibitor-substituted therapy group 
and −0.71 log10 copies/mL in the NNRTI-substituted ther-
apy group, demonstrating that rilpivirine has significant 
antiviral activity against HIV-1 in treatment-experienced 
patients.
A large, randomized Phase IIb dose-ranging study 
that compared the antiviral activity of rilpivirine (25 mg, 
75 mg, or 150 mg) and efavirenz administered as triple 
therapy in treatment-naïve patients at 48 weeks and 96 
weeks found no statistically significant difference in viral 
suppression or CD4 gain.11 Virological failure was similar 
for both groups (6% for rilpivirine vs 7% for efavirenz). 
The proportion of patients developing treatment-emergent 
NNRTI resistance-associated mutations was similar 
between the groups.
Finally, in a large pooled analysis of two ongoing 
randomized Phase III trials (1368 patients) rilpivirine 
showed noninferior efficacy compared with efavirenz at 
48 weeks.15 Virological failure was higher in the rilpivirine 
group (9% vs 4.8%), while the incidence of adverse events 
leading to trial discontinuation was higher in the efavirenz 
group (8% vs 3%). A difference in virologic response 
favoring efavirenz was noted for patients in whom HIV 
RNA was .100,000 copies at study initiation. An effect HIV/AIDS – Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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of   low-dose rilpivirine could not be excluded in the 
  intent-to-treat analysis, in which   discontinuation due to 
adverse events, death, and other reasons, was considered as 
failure. Failure on rilpivirine was due to virological failure, 
exposing patients to resistant mutations both for NNRTI and 
for NRTI, whereas failure among those exposed to efavirenz 
was related to the occurrence of adverse events, with no 
risk for compromising future   treatment options. Among 
successfully genotyped patients, 68% of patients exposed 
to rilpivirine and 32% of patients exposed to efavirenz had 
emergent NRTI mutations, the most frequent NRTI mutation 
with rilpivirine being M184I (the lamivudine/emtricitabine 
mutation that often precedes and is replaced by M184V). 
Rates of emerging NNRTI-related mutations were similar 
between the two groups (50% for rilpivirine vs 43% for efa-
virenz). The most frequent NNRTI mutation to emerge upon 
rilpivirine failure was E138K, a mutation associated with 
resistance to etravirine, efavirenz, and nevirapine in vitro, 
whereas the K103N was most frequent for efavirenz.16 This 
trial is planned to continue through to 96 weeks.
Further studies underway include a comparison of the 
safety, efficacy, and tolerability of rilpivirine in adolescents 
(Clinical trials.gov identifier: NCT0799864), a Phase III trial 
to evaluate the new combination of tenofovir/emtricibitane 
and rilpivirine as a fixed-dose combination in treatment-
naïve patients (NCT00540449), and two trials to evaluate 
switching from regimens consisting of a ritonavir-boosted 
protease inhibitor and two NRTIs or efavirenz and two NRTIs 
to a fixed-dose combination of emtricitabine, rilpivirine, and 
tenofovir (NCT01252940, NCT01286740). A bioavailability 
study in healthy adult volunteers to evaluate three pediatric 
formulations of rilpivirine (a solution, a suspension, and 
granules) compared with an adult tablet formulation has 
recently been completed (Trial NCT00812292), but has yet 
to be reported.
Safety and tolerability
The most extensive safety and tolerability data to date come 
from the 96-week Phase IIb trial, in which the median dura-
tion of follow-up extended to over 100 weeks.11 This study 
reported that rilpivirine was safe and well tolerated across 
a range of doses from 25 mg to 150 mg.
The overall incidence of Grade 2–4 events poten-
tially related to the drug was lower for patients receiving 
rilpivirine compared with efavirenz (20.4% vs 37.1%, 
P = 0.003). Events included nausea, dizziness, abnormal 
dreams/  nightmare, dyspepsia, asthenia, rash, somnolence, 
and vertigo. None of these events were reported in more HIV/AIDS – Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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than 4% of patients, and all were less frequently reported 
in patients receiving rilpivirine compared with efavirenz. 
Incidence of Grade 2–4 rash was also statistically signifi-
cantly lower among patients randomized to rilpivirine (3.2% 
versus 11.2%, P , 0.05).
Grade 3 or 4 adverse events potentially related to the 
drugs were infrequent and statistically similar (5.4% for 
rilpivirine and 7.9% for efavirenz). Grade 3 or 4 laboratory 
abnormalities in hemoglobin occurred in 2.2% of patients, 
and all were in the rilpivirine groups. However, hemoglobin 
levels declined for all groups, and recovered throughout the 
course of the trial, returning to baseline levels in all groups 
and even increasing above baseline at week 96. Incident 
anemia developed predominantly in the subgroup of patients 
using zidovudine/lamivudine as the NRTI backbone.11
Incidence of serious adverse events was similar at 12.2% 
for rilpivirine and 14.6% for efavirenz. Events considered 
at least possibly related to study medication occurred in 
one patient receiving efavirenz (arthralgia) and five patients 
receiving rilpivirine (aspartate aminotransferase/alanine 
aminotransferase increase/cytolytic hepatitis, blood amylase 
increase, abdominal pain/constipation, attempted suicide, 
and anemia).
There were no consistent or clinically relevant changes 
in vital signs among patients on rilpivirine. Increases in QTc 
interval had been observed at week 48 with all rilpivirine 
doses and with efavirenz, but these changes stabilized 
from week 48 onwards. This increase was seen in patients 
receiving zidovudine/lamivudine, but not with tenofovir/ 
emtricitabine.11 The smallest increases to QTc were observed 
with the 25 mg rilpivirine dose.29,36 The clinical signifi-
cance of the QTc prolongation in patients with and without 
  established cardiac conditions is not known.
Further evidence of the side effect profiles of rilpivirine 
and efavirenz comes from the 48-week interim pooled 
analysis of the two ongoing Phase III trials.15 In this analy-
sis, rilpivirine resulted in fewer discontinuations for adverse 
events and fewer instances of neurologic and psychiatric 
adverse events, lipid elevations, and rash, compared with 
efavirenz (Table 3). In view of similar efficacy and safety 
across treatment arms, the 25 mg dose was selected for 
Phase III development.
Safety in pregnancy has not been directly assessed 
because pregnant women are excluded from clinical trials, 
in keeping with prevailing ethical norms. However, stud-
ies in rats and rabbits have not found any adverse effect of 
rilpivirine on fertility, embryonic development, prenatal and 
postnatal development, or the immune system.37 To date, 
there are no published data on the incidence of lipodystrophy 
in patients exposed to rilpivirine.
Perspectives for resource-limited 
settings
The choice of preferred antiretroviral drug regimens in 
resource-limited settings depends on a number of characteris-
tics and constraints common to these settings. First, regimens 
must be efficient and robust. Second, the regimens must be as 
affordable as possible. Third, because care is mainly provided 
at the primary care level by lesser-trained health workers with 
minimal laboratory monitoring, they must have minimal side 
effects. Fourth, they should be compatible with other commonly 
used drugs, in particular tuberculosis medications. Fifth, they 
should be safe and effective for patient groups that are more 
commonly in need in resource-limited settings, in particular 
women of childbearing age and children. Finally, they should be 
available as fixed-dose combinations to maximize adherence.4 
Rilpivirine has some, but not all, of these characteristics. 
Clinical trial data reported to date demonstrate good 
efficacy, but the fact that around half of patients who fail 
rilpivirine develop NNRTI resistance mutations is a cause 
for concern.
The cost of the active pharmaceutical ingredients of anti-
retroviral drugs can account for between 5%–99% of direct 
manufacturing costs.38 In the case of rilpivirine, the active 
pharmaceutical ingredient can be manufactured at a very low 
price, as low as $US10 per patient/year. The lower dosage 
also allows for coformulation with other drugs.
A fixed-dose of rilpivirine, emtricitabine, and tenofovir has 
been evaluated and found to have comparable   bioequivalence 
Table 3 Summary of adverse event data from Phase III trials15
TMC-278 
(686 patients)
Efavirenz 
(682 patients)
P value 
Median treatment 
duration, weeks
56 56
Grade 2–4 adverse 
events (%)
16 31 ,0.0001
Discontinuation due 
to adverse events
3 8 0.0005
Most common adverse events
Any neurological 
adverse events
17 38 ,0.0001
Dizziness 8 26 ,0.0001
Any psychiatric 
adverse events
15 23 0.0002
Abnormal dreams/
nightmares
8 13 0.0061
Rash (any type) 3 14 ,0.0001HIV/AIDS – Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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with the individual drugs.30 For resource-limited settings, the 
combination of rilpivirine, lamivudine, and tenofovir could 
potentially cost at least one-third less than the alternative 
combination of efavirenz, lamivudine, and tenofovir (US$114 
vs US$ 176 per patient/year).39 However, current licensing 
arrangements for generic manufacture are too restrictive 
because they are limited to specific companies and exclude 
a number of high HIV-burden countries,40 including South 
Africa and Brazil, which account for a substantial proportion 
of the total number of people receiving antiretroviral therapy 
in low-income and middle-income countries.41 In order to 
facilitate the development of fixed-dose combinations and 
encourage reduced prices through increased competition, a 
number of international agencies, including the World Health 
Organization, the Joint United Nations Programme on HIV/
AIDS, and the Médecins Sans Frontières, have called for the 
inclusion of rilpivirine into the Medicines Patent Pool.42
The long half-life of rilpivirine suggests a potential 
for monthly dosing via nonoral formulations. An inject-
able nanosuspension of rilpivirine has been developed 
and showed a promising pharmacokinetic profile in both 
animals and humans.12,17 A 600 mg intramuscular injection 
was found to result in sustained release of rilpivirine, and 
simulation of the pharmacokinetic profile predicted a once-
monthly delivery similar to oral dosing with 25 mg once 
daily.17 Unfortunately, a clinical trial aimed at determining 
the safety, tolerability, and long-term plasma exposure 
over time of a one-dose regimen of four monthly subcu-
taneous doses of a long-acting formulation of rilpivirine 
(NCT00741741) has been terminated prematurely, although 
the results of this trial have yet to be placed in the public 
domain. The benefit of such a long-acting formulation in 
terms of adherence would depend on coadministration with 
other drugs that could be administered at similar intervals. 
Drugs currently in development that show potential for 
combination with rilpivirine in a long-acting formulation 
include GSK-572, GSK-744, CMX-157, and elvucitabine 
(although currently no further clinical development is 
planned for the latter drug).
The clinical efficacy of the lowest drug dose has to be 
proven over the long term. Trial data suggest that use of ril-
pivirine in patients with high viral load at treatment initiation 
may be precluded.15 The side effect profile of rilpivirine is 
at least equivalent to and potentially even better than nevi-
rapine and efavirenz, the two most common antiretroviral 
  medications used in resource-limited settings.15
However, the safety and efficacy of rilpivirine in specific 
patient groups remains to be evaluated. No studies have 
yet been undertaken to assess rilpivirine in children under 
12 years of age, although a bioavailability study evaluating 
a solution, suspension, and granules compared with adult 
rilpivirine tablets has been completed (NCT00812292).
Rilpivirine as prevention,  
treatment, or both?
Several recent studies have demonstrated the potential for 
antiretrovirals in preventing HIV infection. One study (the 
Pre-Exposure Prophylaxis Initiative [IPreX]) found that men 
who have sex with men taking daily tenofovir/emtricitabine 
as pre-exposure prophylaxis were 44% less likely to become 
HIV-infected compared with those taking placebo.43 The good 
tolerability of oral tenofovir as pre-exposure prophylaxis 
among men who have sex with men was confirmed by a 
  second study (CDC-4323),44 while a third study (Center for 
the AIDS Program of Research in South Africa [CAPRISA] 
004) demonstrated that tenofovir applied as a vaginal gel 
reduced the risk of contracting HIV by 39% in women.45
Antiretroviral medications such as rilpivirine that can 
be administered as long-acting formulations have particular 
interest as prevention interventions because they provide the 
potential for weekly or monthly administration. This advan-
tage is evident from the results of the IPreX trial, in which 
poor adherence to daily tenofovir treatment compromised the 
overall effect size of the trial. A preclinical evaluation of the 
potential prophylactic application of rilpivirine at a range of 
intervals would be the logical first step.
There are also broader considerations. The use of any 
antiretroviral as pre-exposure prophylaxis will require admin-
istering these drugs to many more people than for treatment 
alone, and this raises a number of ethical concerns, including 
fair allocation (who is prioritized for pre-exposure prophy-
laxis, and who will pay), and the potential for speeding up the 
development of resistance to drugs used for pre-exposure pro-
phylaxis, which may lead to recommendations to withhold a 
drug with preventive potential from being used in treatment.46 
Given the potential usefulness of rilpivirine as both prevention 
and treatment, careful consideration will be needed in order 
to ensure that this drug is used to the greatest benefit.
Conclusion
The vast majority of people living with HIV/AIDS reside 
in the developing world, in settings characterized by limited 
health budgets, critical shortages of doctors, limited labora-
tory monitoring, a substantial burden of pediatric HIV , and 
high rates of coinfection, in particular with tuberculosis. 
Therefore, the extent to which new antiretrovirals will HIV/AIDS – Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
43
Safety, efficacy, and pharmacokinetics of rilpivirine
  contribute to improvements in the management of HIV 
globally will depend to a large extent on their affordability, 
ease of use, limited toxicity, pediatric formulations, and 
compatibility with tuberculosis and other drugs that are com-
monly prescribed for people living with HIV/AIDS.
The development of rilpivirine to date has taken many, 
but not all, of these issues into account. Overall, the low dose 
(allowing for low cost and coformulation), good efficacy and 
safety profile, and potential for formulation in fixed-dose 
combinations, and ongoing development of pediatric for-
mulations, makes rilpivirine an attractive drug for resource-
limited settings. Disadvantages of this drug include limited 
robustness and important potential drug-to-drug interactions, 
in particular with antituberculosis drugs. Future research 
should consider the potential for increasing robustness with-
out increasing toxicity using higher doses, the clinical signifi-
cance of the interaction between rilpivirine and tuberculosis 
drugs, and the safety and efficacy of pediatric formulations. 
Finally, policies are needed to overcome   intellectual property 
barriers to the development of fixed-dose combinations and 
to ensure access and affordability for all people living with 
HIV/AIDS.
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